Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04565171
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04552808
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chendu, Sichuan, China
GLS4/RTV and TAF Drug-drug Interaction
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04551261
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04546984
- Locations
- 🇨🇳
The Shanghai xuhui district central hospital, Shanghai, Shanghai, China
Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT04536532
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04512170
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT04422496
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Melbourne VIC 3004, Australia
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 416
- Registration Number
- NCT04415853
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04324372
- Locations
- 🇨🇳
The Fifth Medical Center of PLA Ceneral Hospital, Beijing, China/BEIJING, China
Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04232514
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
© Copyright 2024. All Rights Reserved by MedPath